Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MapKure Doses First Patient in Australian Phase I Trial of BeiGene's B-RAF Inhibitor

publication date: Feb 27, 2020

MapKure, a JV formed by Beijing's BeiGene and SpringWorks Therapeutics of Connecticut, has dosed the first patient in an Australian trial of BeiGene's second-gen B-RAF inhibitor. BGB-3245 is aimed at patients with advanced or refractory solid tumors that have B-RAF mutations. SpringWorks was formed in 2017 as a spin-out from Pfizer with two Pfizer targeted small-molecule oncology drugs. MapKure is also starting a Phase I trial in the US of BGB-3245, which will be an expansion of the Australian trial. More details....

Stock Symbols: (NSDQ: BGNE; HKEX: 06160) (NYSE: PFE)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here